ClinConnect ClinConnect Logo
Search / Trial NCT06157268

The Natural History and Muscle Fatigability of Patients With Congenital Myopathies.

Launched by RADBOUD UNIVERSITY MEDICAL CENTER · Nov 27, 2023

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

Natural History Study Outcome Measures Congenital Myopathy Muscle Disease

ClinConnect Summary

This clinical trial is focused on understanding the natural history and muscle fatigue in patients with three rare types of congenital myopathies: Central Core Disease, Multi-Minicore Disease, and Nemaline Myopathy, as well as Centronuclear Myopathy. These conditions can make muscles weaker and cause tiredness during physical activity, but there is currently no cure. Over the next 24 months, researchers aim to learn more about how these conditions progress over time and how muscle fatigue affects daily life for patients.

To participate, individuals must be at least 2 years old and speak Dutch, with a confirmed genetic diagnosis of one of the myopathies mentioned. Those aged 8 to 60 will also be part of a specific study on muscle fatigability. Participants will need to travel to Nijmegen and Utrecht for the study visits and may be asked to stop taking certain medications a day before their appointments. This study is a chance for patients and their families to contribute to important research that could help improve understanding and treatment of these conditions in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria for the natural history:
  • 2 years or older
  • Willing and able to complete the measurement protocol
  • Willing and able to travel to Nijmegen and Utrecht
  • Dutch-speaking
  • Genetically-confirmed congenital myopathy (CCD/MmD, NEM, and CNM)
  • Inclusion Criteria for the fatigability study:
  • 8-60 years old
  • Willing and able to complete the measurement protocol
  • Willing and able to travel to Nijmegen and Utrecht
  • Dutch-speaking
  • Genetically-confirmed congenital myopathy (CCD/MmD, NEM, and CNM)
  • Willing to stop taking pyridostigmine and/or salbutamol 24 hours before the visit.
  • Exclusion Criteria for both parts:
  • Other neuromuscular, psychiatric or neurological disorders.

About Radboud University Medical Center

Radboud University Medical Center is a leading academic medical institution located in Nijmegen, the Netherlands, dedicated to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, Radboud UMC leverages its multidisciplinary expertise to conduct high-quality research that aims to improve patient outcomes and enhance medical knowledge. The center is committed to ethical standards and regulatory compliance, fostering collaboration among researchers, healthcare professionals, and patients to translate scientific discoveries into effective clinical applications. With a focus on personalized medicine and cutting-edge technologies, Radboud University Medical Center plays a pivotal role in shaping the future of healthcare through its rigorous clinical trial initiatives.

Locations

Utrecht, , Netherlands

Nijmegen, Gelderland, Netherlands

Patients applied

0 patients applied

Trial Officials

Nicol Voermans, MD PhD

Principal Investigator

Radboud University Medical Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported